(Press-News.org) Adolescent smokers have thicker artery walls indicative of early development of atherosclerosis, according to research presented today at the ESC Congress. The findings from the Sapaldia Youth Study were presented by Dr Julia Dratva from Switzerland.
Early exposure to tobacco smoke is associated with various adverse health outcomes in children and adolescents, including low birth weight and impaired lung growth and function. Tobacco smoke is considered highly atherogenic in adults, but little is known about the impact of tobacco smoke exposure on cardiovascular health in adolescents. Children and adolescents are exposed to tobacco smoke through passive and active smoking.
Atherosclerosis is a multi-factorial disease which begins in childhood and in utero. Tobacco smoke exerts its effects through toxic compounds which cross the placental barrier and alveolar wall of the lungs. This leads to increased local and systemic inflammation.
The Swiss Study on Air Pollution And Lung and Heart Disease In Adults (SAPALDIA) is a multicentre study of nearly 10,000 subjects. The SAPALDIA Youth Study included 351 offspring of SAPALDIA participants aged 8 -20 years. It investigated the cardiovascular risk profile and the association between active smoking and carotid artery intima-media thickness (CIMT), an early indicator of atherosclerotic changes in the vessel wall.
For the current study presented at the ESC Congress, 288 of the offspring underwent a clinical examination following a standardized protocol: anthropometry, blood pressure, ultrasound CIMT assessment, and blood tests for cardiovascular biomarkers. Subjects reported their level of physical activity, smoking status and exposure to passive smoking. Cotinine testing was used to validate smoking status and exposure to passive smoke.
Regular current smoking (daily/weekly) was reported by 11% of the 288 offspring (mean age 15 years; 53% girls) and by 15% when including less frequent smokers (monthly). Mean smoking duration was 2.3+1.98 years in ever-smokers. Exposure to passive smoke up to 10 years of age was reported by 31% of subjects and current parental smoking by 25%. Three per cent of adolescents were obese, 13% overweight and 60% reported less than 4 hours of either strenuous or moderate activity per week. Parental history of cardiovascular disease or cardiovascular risk factors were present in 22% of the participants.
CIMT is an accepted indicator of atherosclerosis in all age groups. In this study the mean CIMT in all subjects was 0.50+0.08mm. Multivariate regression analyses showed a significant effect of regular current smoking, with an increase in CIMT of 0.043mm (95%CI=0.014-0.073). "The results remained consistent when adjusting additionally for parental smoking, which means that the association observed was not confounded by parental smoking," said Dr Dratva. "Smoking duration was positively associated with CIMT, showing that the longer subjects smoked, the greater their carotid artery intima-media thickness." The independent role of passive smoking on the artery wall in childhood is currently being investigated in the SAPALDIA Youth Study.
She added: "Our study in adolescents addresses important early risk factors of cardiovascular health in adolescents. After a relatively short duration of active smoking, the vascular structure already shows signs of structural changes, compared to non-smoking adolescents. These results give evidence of an early adverse impact of active tobacco exposure on the vasculature, which is indicative of early development of atherosclerosis."
Dr Dratva continued: "Urgent action is needed to help adolescent smokers kick the habit and stop others from taking up smoking. More research is required to determine whether the damage to the vascular structure of smoking adolescents is reversible if they quit smoking."
###
Contributors:
Julia Dratva1, Nino Kuenzli1, Arno Schmidt-Trucksäss2, Eric de Groot3, Robert Bettschart4, Thomas Rothe5, Daiana Stolz6, Alexander Turk7, Jean-Michel Gapoz8, Thierry Rochat9 , Nicole Probst-Hensch1, Elisabeth Zemp1
1Swiss Tropical and Public Health Institute, Basel, Switzerland; 2Institute of Exercise and Health Sciences, Sports Medicine, University of Basel, Switzerland; 3Vascular Medicine, AMC , Amsterdam and Imagelabonline, Eindhoven, the Netherlands; 4Lungenpraxis Aarau, Switzerland; 5Spital Davos, Davos, Switzerland; 6Universitätsspital, Pneumologie, Basel, Switzerland; 7Zürcher Höhenklinik, Wald-Faltigberg, Switzerland; 9Department of Community Medicine and Primary Care, University Hospitals, Geneva, Switzerland; 8Hôpitaux Universitaires, Service de Pneumologie, Geneva, Switzerland
Notes to editors
The SAPALDIA Youth Study was funded by the Swiss National Foundation (Marie Heim-Vögtlin Stipendium, www.snf.ch), the Lungenliga beider Basel and Davos, as well as by the Stiftung vormals Bünder Heilstätte. The SAPALDIA cohort supported the offspring study in infrastructure, staff and finances.
About the European Society of Cardiology www.escardio.org
The European Society of Cardiology (ESC) represents more than 75,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
About ESC Congress 2012
The ESC Congress is currently the world's premier conference on the science, management and prevention of cardiovascular disease. ESC Congress 2012 takes place 25-29 August at the Messe München in Munich. The scientific programme is available here.
More information is available from the ESC Press Office at press@escardio.org.
Adolescent smokers have artery damage
2012-08-27
ELSE PRESS RELEASES FROM THIS DATE:
Heart separation device improves 3 year outcomes in heart failure patients
2012-08-27
Munich, Germany – A novel non-invasive device which separates healthy and damaged heart muscle and restores ventricle function improves 3 year outcomes in patients with ischemic heart failure, according to research presented at the ESC Congress 2012. The findings were presented by Professor William T. Abraham at an ESC press conference on 25 August and by Dr Marco Costa at an ESC Congress scientific session on 27 August.
Heart failure is a common, debilitating, and potentially deadly condition in which the heart is unable to supply sufficient blood flow to meet the needs ...
Promising new drug target discovered for treatment and prevention of heart failure
2012-08-27
Munich, Germany – A promising new drug target for the treatment and prevention of heart failure has been discovered by researchers at Mount Sinai School of Medicine in New York, NY, US. The study was presented at the ESC Congress 2012 by principal investigator Professor Roger J. Hajjar, MD.
According to the US Centers for Disease Control and Prevention, about 5.8 million Americans suffer from heart failure and 670,000 new cases are diagnosed each year. One in five people with heart failure die within one year of diagnosis. Heart failure is most often treated with aggressive ...
Novel anti-platelet therapy reduces risk of cardiac events in patients with history of heart attack
2012-08-27
According to new research from Brigham and Women's Hospital (BWH), adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the long-term risk of recurrent cardiovascular events beyond one year in patients with a history of a prior heart attack. Researchers also identify a low-bleeding risk group among whom the clinical benefit of vorapaxar was particularly favorable. This research is presented at the European Society of Cardiology Congress 2012 and published simultaneously in the Lancet.
For more than a million Americans ...
The PURE study
2012-08-27
Munich, Germany – Healthy foods such as fruits and vegetables, proteins and non-saturated fats are consumed more often by the wealthy while poorer people consume more carbohydrates, concludes a new study involving people from 17 countries.
Results from the Prospective Urban Rural Epidemiology (PURE) study were reported here today by Professor Salim Yusuf of the Population Health Research Institute, McMaster University and Hamilton Health Sciences, in Hamilton, Canada and principal investigator of the study. The study,
involving 154,000 individuals from 628 communities, ...
The DeFACTO study
2012-08-27
Munich, Germany – Data presented today from the prospective Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography (DeFACTO) study show that, when compared to standard coronary angiography (CT), the non-invasive assessment of fractional flow reserve by computed tomography (FFRct) provides a more accurate determination of which lesions require invasive evaluation.(1)
The results of the study were presented by Dr James K. Min, director of Cardiac Imaging Research and co-director of Cardiac Imaging at the Department of Medicine, Imaging and ...
Median follow-up results from the ALTITUDE study, stopped prematurely in December 2011
2012-08-27
Munich, Germany – Preliminary results from the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) do not support administration of aliskiren on top of standard therapy with renin-angiotensin-aldosterone system (RAAS) blockade in type 2 diabetics at high risk of cardiovascular and renal events, according to Professor Hans-Henrik Parving from Rigshospitalet, University of Copenhagen, Denmark. Presenting results from the study today, he said the treatment "may even be harmful".
The ALTITUDE trial was stopped prematurely in December 2011 on recommendation ...
The TRILOGY ACS study
2012-08-27
Munich, Germany – The first trial to study the effect of platelet inhibition in patients with acute coronary syndromes managed medically without revascularisation has found no significant difference between prasugrel and clopidogrel in the prevention of death, myocardial infarction or stroke.
The findings, from the phase III Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) study, were presented today at a Hot Line session of ESC Congress 2012 in Munich.
TRILOGY ACS was double-blind, randomised trial ...
The PARAMOUNT study
2012-08-27
Munich, Germany – The novel angiotensin receptor neprilysin inhibitor, LCZ696, demonstrated beneficial effects in heart failure patients with preserved ejection fraction (HFpEF), according to results of the PARAMOUNT (Prospective compArison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion) trial.
Approximately half of all heart failure patients have normal or nearly normal ejection fraction, a measure of their strength of cardiac contraction. However, while many studies have shown a benefit of pharmacological therapies in heart failure ...
The Aldo-DHF study
2012-08-27
Munich, Germany – Mineralocorticoid receptor antagonists should be considered as a treatment option in hypertensive patients with diastolic heart failure, said Professor Burkert Pieske presenting results today of the Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) study at ESC Congress 2012.
Behind his conclusion lay results showing that mineralocorticoid receptor blockade with spironolactone improves cardiac function and structure, reduces neuroendocrine activation, and effectively reduces blood pressure in a patient population with symptomatic predominantly ...
Obesity triggers AF in fertile women
2012-08-27
Munich, Germany – Obesity triggers atrial fibrillation in fertile women, according to research presented today at the ESC Congress 2012 by Dr Deniz Karasoy from Denmark.
Atrial fibrillation and obesity are among the largest public health related challenges in the western world today. Atrial fibrillation is the commonest heart rhythm disorder and is associated with increased mortality and morbidity. Previous studies have demonstrated that obesity increases the risk of new-onset atrial fibrillation in individuals with known risk factors for developing atrial fibrillation ...